Related Experiment Video

Updated: Apr 2, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

Zuzanna Baranski1, Yvonne de Jong2, Trayana Ilkova1

  • 1Division of Toxicology, Leiden/Academic Center for Drug Research, Leiden University, 2300 RA Leiden, The Netherlands.

Oncotarget
|September 30, 2015
PubMed

Insights

This study identifies Bcl-xL as a key target for overcoming chemotherapy resistance in osteosarcoma. Inhibiting Bcl-xL enhances cancer cell death, offering a new strategy for treating this bone cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • High-grade conventional osteosarcoma, a primary bone tumor, has a poor prognosis.
  • Chemotherapy resistance is a significant challenge in treating osteosarcoma patients.

Purpose of the Study:

  • To identify critical regulators of osteosarcoma cell survival within the Bcl-2 family.
  • To explore the potential of targeting Bcl-2 family members for overcoming chemotherapy resistance.

Main Methods:

  • Conducted an siRNA screen targeting Bcl-2 family members in human osteosarcoma cell lines.
  • Investigated the effects of silencing Bcl-xL and Bak on cell viability, cell cycle, and apoptosis.
  • Evaluated the efficacy of pharmacological Bcl-xL inhibition in combination with doxorubicin.

Main Results:

  • Silencing Bcl-xL induced apoptotic cell death, while silencing Bak impaired cell cycle progression and triggered autophagy.
  • Bcl-xL was expressed in clinical osteosarcoma samples, but expression levels did not correlate with therapy response or survival.
  • Pharmacological inhibition of Bcl-xL synergistically enhanced the response to doxorubicin, particularly in cells with high Bcl-xL expression.

Conclusions:

  • Bcl-xL is identified as a potential drug target for sensitizing osteosarcoma to chemotherapy.
  • Targeting Bcl-xL, using agents like WEHI-539, can enhance chemotherapy-induced apoptosis in osteosarcoma.
Keywords:
Bcl-xLapoptosisautophagydoxorubicinosteosarcoma

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K